Analyst: Genmab cancer data is promising compared to rival
![Photo: Tuala Hjarnø / Genmab / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13997532.ece/ALTERNATES/schema-16_9/doc7kvk0xt87kix8fvllga.jpg)
On Saturday, Genmab reported all data from a successful phase II study of drug candidate epcoritamab as a treatment for large B-cell lymphoma (LBCL).
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Genmab presents full data set for cancer drug
For subscribers
New arbitration full of upsides for Genmab, says analyst
For subscribers
Genmab receives orphan drug designation from FDA
For subscribers